BlossomHill Therapeutics, Inc. (BLSM)

BlossomHill Therapeutics Financials Overview

Financials in millions USD. Fiscal year is January - December.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024
Operating Income Operating Income Growth	-85.24	-64.02	-36.4
Net Income Net Income Growth	-81.6	-60.56	-30.7
Earnings Per Share EPS Growth	-31.83	-24.83	-13.40
EPS Growth	-	-	-

Cash & Debt

Chart

Fiscal Year	Current	FY 2025	FY 2024
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024
Cash & Investments Cash & Investments Growth	95.38	136.68	100.15
Total Debt Total Debt Growth	23.37	22.4	0.53
Net Cash (Debt) Net Cash Growth	72.01	114.28	99.62
Net Cash Growth	-	14.72%	-
Net Cash Per Share Net Cash Per Share Growth	28.08	46.87	43.50

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024
Operating Cash Flow Operating Cash Flow Growth	-70.98	-46.93	-31.42
Capital Expenditures CapEx Growth	-0.08	-1.07	-0.09
Free Cash Flow Free Cash Flow Growth	-71.06	-47.99	-31.51
Free Cash Flow Growth	-	-	-

Data Source: S&P Global Market Intelligence Last updated: Sep 18, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 17, 2026

Data Sources Report a data error